@article{2e4496be4cf54666be5dcd5755e0eb04,
title = "Chronic staphylococcal osteomyelitis: Treatment with regimens containing rifampin",
abstract = "Experience with rifampin as a component of combination antibiotic therapy for chronic staphylococcal osteomyelitis was reviewed. These data included the preliminary results of a randomized, prospective trial of parenteral nafcillin alone vs. parenteral nafcillin plus oral rifampin; the results of use of rifampin in combination with other oral antibiotics for the treatment of chronic staphylococcal osteomyelitis; and experience with rifampin regimens at the Oregon Health Sciences University. A total of 28 patients are described in this report; 70% of those who received regimens including rifampin experienced an apparent cure of infection. Most patients whose infections were not cured had inadequate surgical therapy or were also infected with other bacteria. Staphylococcus aureus was eradicated from the sinus drainage of all but one patient. Although these results are encouraging, a larger number of patients and a longer follow-up period are required for an adequate evaluation of the place of rifampin in therapy for chronic staphylococcal osteomyelitis.",
author = "{Chronic Staphylococcal Osteomyelitis Study Group} and Norden, {Carl W.} and Joshua Fierer and Bryant, {Richard E.} and Palmer, {Darwin L.} and Jones, {Steve M.} and Bird, {Charles B.} and Hartstein, {Alan I.} and Joseph Wheat and Moellering, {Robert C.} and Karchmer, {Adolf W.} and Montgomerie, {John Z.} and Aber, {Robert C.} and Robert Greer and Carl Norden and Monto Ho and Allen, {J. Weinstein} and Phair, {John P.} and Sande, {Merle A.} and Mandell, {Gerald L.} and Dale Daniel and Craig, {William A.} and Mader, {Jon T.} and Reinarz, {James A.}",
note = "Funding Information: The prospective, randomized rifampin protocol was set up with the help of Dr. John Eble and was sponsored by Dow Chemical Company. Studies by Dr. Fierer were supported by Ciba Pharmaceutical Company. We thank Drs. Jay P. Sanford and David N. Gilbert for their advice and assistance in the early stages of development of the protocol. Written, informed consent was obtained from all patients in this study. Please address requests for reprints to Dr. Richard E. Bryant, Division of Infectious Disease, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, Oregon 97201.",
year = "1983",
month = jul,
doi = "10.1093/clinids/5.Supplement_3.S495",
language = "English (US)",
volume = "5",
pages = "S495--S501",
journal = "Reviews of infectious diseases",
issn = "0162-0886",
publisher = "Oxford University Press",
}